If you're treating or encountering bladder cancer in your practice, you don't want to miss the 6th International Bladder Cancer Update, a CME conference hosted this year at The Westin Kierland Resort and Spa, Scottsdale, Arizona, November 18-20, 2022. There are a lot of new advances in this space and there's a lot to keep up with.
IBCU assembled a world-class faculty and agenda that will keep you informed on the latest treatments and research in this important field. Hope you'll join the IBCU in Scottsdale!
Session I: Bladder Cancer Treatment: An Evolution In Progress - Moderator: Seth P. Lerner, MD
▪ The Contribution of SWOG to Bladder Cancer Clinical Trials ▪ Alternative Payment Models - Value Care Bundling ▪ Panel Discussion: What Does the Future Hold?
▪
The Contribution of SWOG to Bladder Cancer Clinical Trials
▪
Alternative Payment Models - Value Care Bundling
▪
Panel Discussion: What Does the Future Hold?
Session II: Management of Non-muscle Invasive Bladder - Moderator: Sam S. Chang, MD, MBA
▪ Controversies in NMIBC: Guidelines and Beyond ▪ Use of Biomarkers in NMIBC: What’s New? And What Should We Use? ▪ Risk Stratification: Moving from the Old to the New
▪
Controversies in NMIBC: Guidelines and Beyond
▪
Use of Biomarkers in NMIBC: What’s New? And What Should We Use?
▪
Risk Stratification: Moving from the Old to the New
Session III: Challenging Case Presentations - Moderator: Mark D. Tyson, II, MD, MPH
Discussants: Peter Black, MD, Jennifer A. Linehan, MD, Joshua J. Meeks, MD, PhD, Parminder Singh, MD
Session IV: Advanced Urothelial Cancer Part 1 - Moderator: Daniel P. Petrylak, MD
▪ Impact of Immunotherapy ▪ Immune Checkpoint Inhibitors ▪ Immune Checkpoint Inhibitors: Combination Therapy ▪ Immune Checkpoint Inhibitors: Managing ▪ Immune-related Side Effects ▪ Earlier Use of These Treatments Moving Into Adjuvant and NMIBC: What Do We Do About Patients for Reinduction of Immune Treatment? ▪ Panel Discussion: Future Challenges to the Use of Immunotherapy: What’s the Right Timing and Sequencing?
▪
Impact of Immunotherapy
▪
Immune Checkpoint Inhibitors
▪
Immune Checkpoint Inhibitors: Combination Therapy
▪
Immune Checkpoint Inhibitors: Managing
▪
Immune-related Side Effects
▪
Earlier Use of These Treatments Moving Into Adjuvant and NMIBC: What Do We Do About Patients for Reinduction of Immune Treatment?
▪
Panel Discussion: Future Challenges to the Use of Immunotherapy: What’s the Right Timing and Sequencing?
Session V: Advanced Urothelial Cancer Part 2: Latest Research and Clinical Trials - Moderator: Daniel P. Petrylak, MD
▪ FGFR Kinase Inhibitors and Other Novel Targets in the Treatment of Metastatic Urothelial Cancer ▪ The Use of Antibody-drug Conjugates in Treating Advanced Urothelial Cancer ▪ Targeted Therapy Combined with Immune Checkpoint Therapy: Is This the Wave of the Future? ▪ Biomarker Integration for Advanced Urothelial Carcinoma ▪ Panel Discussion / Questions and Answers
▪
FGFR Kinase Inhibitors and Other Novel Targets in the Treatment of Metastatic Urothelial Cancer
▪
The Use of Antibody-drug Conjugates in Treating Advanced Urothelial Cancer
▪
Targeted Therapy Combined with Immune Checkpoint Therapy: Is This the Wave of the Future?
▪
Biomarker Integration for Advanced Urothelial Carcinoma
▪
Panel Discussion / Questions and Answers
Session VI: Management of UTUC - Moderator: Jennifer A. Linehan, MD
▪ UTUC – Is it Biologically Distinct? ▪ Methods and Guidelines to Stage and Grade (Low vs. High) UTUC and How Should We Treat? ▪ Treatment of Advanced UTUC ▪ Panel Discussion / Questions and Answers
▪
UTUC – Is it Biologically Distinct?
▪
Methods and Guidelines to Stage and Grade (Low vs. High) UTUC and How Should We Treat?
▪
Treatment of Advanced UTUC
▪
Panel Discussion / Questions and Answers
Session VII: Management of MIBC - Moderator: Peter Black, MD
▪ Neoadjuvant or Adjuvant Therapy? ▪ What Should I Do About Micropapillae? Do I treat it differently than standard? ▪ Bladder Sparing Regimens for Muscle Invasive Disease: Should We Be Doing this More? ▪ Utilizing Molecular Characterization of Invasive Bladder Cancer: What It Means Now and In the Future
▪
Neoadjuvant or Adjuvant Therapy?
▪
What Should I Do About Micropapillae? Do I treat it differently than standard?
▪
Bladder Sparing Regimens for Muscle Invasive Disease: Should We Be Doing this More?
▪
Utilizing Molecular Characterization of Invasive Bladder Cancer: What It Means Now and In the Future
Program Directors
Sam S. Chang, MD, MBA Vanderbilt University School of Medicine Nashville, Tennessee
Daniel P. Petrylak, MD Yale Cancer Center New Haven, Connecticut
Don't Miss Out: Register Today! Simply head to the 6th IBCU 2022 website to book your place at this event. Register now! The abstract submission deadline is October 21, 2022
You are receiving this mailing as you are signed up to receive news from BLC. You can unsubscibe or alter your preferences at any time by clicking the links below.
